Aligos Therapeutics (ALGS) Assets Average (2020 - 2026)

Aligos Therapeutics has reported Assets Average for 7 years, with the latest figure at $76.5 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average fell 30.66% year-over-year to $76.5 million; the trailing twelve-month figure through Mar 2026 stood at $76.5 million (down 30.66% YoY), and the FY2025 full-year result was $79.3 million, down 28.42% from the prior year.
• Assets Average for Q1 2026 stood at $76.5 million, down from $99.1 million in the prior quarter.
• The five-year high for Assets Average was $222.9 million in Q1 2022, with the low at $76.5 million in Q1 2026.
• Historically, Assets Average has averaged $129.3 million across 5 years, with a median of $118.7 million in 2023.
• Annual changes were most pronounced in 2023 — Assets Average plunged 44.61% — and 2025, when it rose 25.09%.
• Aligos Therapeutics' Assets Average stood at $155.4 million in 2022, then decreased by 23.61% to $118.7 million in 2023, then plunged by 33.22% to $79.3 million in 2024, then grew by 25.09% to $99.1 million in 2025, then fell by 22.8% to $76.5 million in 2026.
• The last three Assets Average figures came in at $76.5 million (Q1 2026), $99.1 million (Q4 2025), and $122.2 million (Q3 2025), per Business Quant data.